These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36386178)

  • 1. Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer.
    Chen X; Xia D; Jiang X; Cao L; Ryu JH; Hu X
    Front Pharmacol; 2022; 13():944685. PubMed ID: 36386178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
    Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
    Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alectinib as a treatment option following recovery from crizotinib-induced interstitial lung disease in patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.
    Nukaga S; Naoki K; Kamo T; Masuzawa K; Yasuda H; Soejima K; Betsuyaku T
    Mol Clin Oncol; 2016 Jun; 4(6):1085-1087. PubMed ID: 27284449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of lorlatinib following alectinib-induced pneumonitis in two patients with
    Myall NJ; Lei AQ; Wakelee HA
    Transl Lung Cancer Res; 2021 Jan; 10(1):487-495. PubMed ID: 33569330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interstitial lung disease induced by alectinib (CH5424802/RO5424802).
    Ikeda S; Yoshioka H; Arita M; Sakai T; Sone N; Nishiyama A; Niwa T; Hotta M; Tanaka T; Ishida T
    Jpn J Clin Oncol; 2015 Feb; 45(2):221-4. PubMed ID: 25398579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK-Rearranged NSCLC With Concomitant HER2-Mutant Breast Cancer Patient Treated With Alectinib, Trastuzumab, and Pertuzumab: A Case Report.
    Takayasu H; Kata Y; Otsu Y; Inoue S; Kaneko T
    Cureus; 2023 Mar; 15(3):e36711. PubMed ID: 37113357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report.
    Misawa K; Nakamichi S; Iida H; Nagano A; Mikami E; Tozuka T; Matsumoto M; Miyanaga A; Noro R; Kubota K; Yamaguchi H; Seike M
    Onco Targets Ther; 2023; 16():65-69. PubMed ID: 36718244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year Disease Control With Alectinib in a Patient With Metastatic ALK-rearranged Lung Adenocarcinoma.
    Ohara G; Sasatani Y; Okauchi S; Satoh H
    Cancer Diagn Progn; 2022; 2(6):707-710. PubMed ID: 36340452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review.
    Gu R; Shi Z; Duan T; Song M
    Onco Targets Ther; 2021; 14():5107-5113. PubMed ID: 34707369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment with alectinib after crizotinib-induced interstitial lung disease.
    Chino H; Sekine A; Kitamura H; Kato T; Ogura T
    Lung Cancer; 2015 Dec; 90(3):610-3. PubMed ID: 26452431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
    Shirasawa M; Kubotaa M; Harada S; Niwa H; Kusuhara S; Kasajima M; Hiyoshi Y; Ishihara M; Igawa S; Masuda N
    Lung Cancer; 2016 Sep; 99():66-8. PubMed ID: 27565916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
    Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
    BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alectinib in the treatment of ocular metastases of ALK rearranged non small cell lung cancer: Description of 2 case reports.
    Gozzi E; Angelini F; Rossi L; Leoni V; Trenta P; Cimino G; Tomao S
    Medicine (Baltimore); 2020 Jul; 99(27):e21004. PubMed ID: 32629718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study.
    Lin JJ; Muzikansky A; Kennedy E; Kuberski H; Stober LL; Wanat AC; Azzoli CG; Lennes I; Sequist LV; Dagogo-Jack I; Shaw AT; Gainor JF
    ESMO Open; 2022 Feb; 7(1):100342. PubMed ID: 34896762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report.
    Makimoto G; Kawakado K; Nakanishi M; Tamura T; Kuyama S
    Case Rep Oncol; 2021; 14(1):197-201. PubMed ID: 33776703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report.
    Kashizaki F; Tanaka A; Sekido Y
    J Med Case Rep; 2022 Aug; 16(1):316. PubMed ID: 35999557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment with crizotinib after alectinib-induced interstitial lung disease.
    Zhu N; Lin S; He L; Wang L; Kong W; Cao C
    SAGE Open Med Case Rep; 2021; 9():2050313X211042991. PubMed ID: 34484794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alectinib Treatment of ALK Positive Non Small Cell Lung Cancer Patients with Brain Metastases: Our Clinical Experience.
    Crvenkova S
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Sep; 41(2):29-36. PubMed ID: 33011694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung.
    Imanishi N; Yoneda K; Taira A; Ichiki Y; Sato N; Hisaoka M; Tanaka F
    Surg Case Rep; 2018 Mar; 4(1):19. PubMed ID: 29524063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer.
    Kimura T; Sowa-Osako J; Nakai T; Ohyama A; Kawaguchi T; Tsuruta D; Ohsawa M; Hirata K
    Case Rep Oncol; 2016; 9(3):826-832. PubMed ID: 28101031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.